


Support for amendments to claim 14 appear at least in, *e.g.*, claim 11 as originally filed. Amendments to claims 19 and 21 are made to remove reference to nonelected subject matter. Support for new claim 28 appears at least in, *e.g.*, page 3, lines 10-15, and page 14, line 27, through page 15, line 11. Support for new claim 29 appears at least in, *e.g.*, page 15, line 31, through page 16, line 7, and on page 16, lines 21-24.

No new matter has been introduced in these amendments. Claim changes are delineated in the appendix entitled "Version With Markings to Show Changes Made".

CONCLUSION

In view of the foregoing, Applicant submits that the application is in condition for allowance and such action is respectfully requested. Should any questions or issues arise concerning the application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Kristin E. Konzak, Reg. No. 44,848
Attorney/Agent for Applicants
c/o MINTZ LEVIN

One Financial Center
Boston, Massachusetts 02111
Tel.: (617) 542-6000
Fax: (617) 542-2241

Date: October 17, 2001

Version With Markings to Show Changes Made

Cancel claims 11 - 13, 15 - 18 and 22 -27 as relating to non-elected subject matter.
Amend claims 14, 19 and 21 as follows:

14. (Amended) A method of producing [the polypeptide of claim 11] an isolated FGF-CX polypeptide at least 80% identical to a polypeptide of SEQ ID NO:2, said method comprising the step of culturing the host cell of claim 10 under conditions in which the nucleic acid molecule is expressed.

19. (Amended) A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of [a therapeutic selected from the group consisting of:

- a)] the nucleic acid of claim 1 [;
 - b) the polypeptide of claim 11; and
 - c) the antibody of claim 13;
-] and a pharmaceutically acceptable carrier.

21. (Amended) The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a proliferative disorder, a differentiative disorder, and a glia-associated disorder, wherein said therapeutic is [selected from the group consisting of:

- a)] the nucleic acid of claim 1 [;
- b) the polypeptide of claim 11; and
- c) the antibody of claim 13].

Insert the following claims:

-- 28. An isolated nucleic acid molecule encoding FGF-CX, said molecule comprising a nucleotide sequence selected from the group consisting of:

- a) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO:1;
- b) a fragment of a nucleic acid sequence comprising a nucleic acid sequence of SEQ ID NO:1, wherein the fragment comprises at least 6 contiguous nucleotides of SEQ ID NO:1;
- c) a derivative of a nucleic acid comprising a nucleic acid sequence of SEQ ID NO:1;
- d) an analog of a nucleic acid comprising a nucleic acid sequence of SEQ ID NO:1;
- e) a homolog of a nucleic acid comprising a nucleic acid sequence of SEQ ID NO:1; and
- f) a naturally occurring allelic variant of a nucleic acid of SEQ ID NO:1, wherein the nucleic acid hybridizes to a nucleic acid molecule of SEQ ID NO:1 under stringent conditions.

29. The nucleic acid of claim 28 wherein the nucleic acid, or a fragment thereof, has an activity selected from the group consisting of:

- a) a fibroblast growth factor-like activity;
- b) a cell proliferative activity;
- c) a glia activating activity; and
- d) a neuroprotective-like activity. --

TRA 1582206v1